Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
NCT04582539 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
- Lead sponsor
- Incyte Corporation
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 19, 2021
- Completion date
- August 15, 2024
- Enrollment
- 22 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.